Clinical Trials
Your involvement is crucial in advancing cardiovascular research related to Lipoprotein(a).
ACCLAIM-Lp(a)
Lp(a)Study Title: A Phase 3, Randomised, DoubleBlind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
Study Sponsor: Eli Lilly and Company
Brief Summary: The main purpose of this study is to learn more about lepodisiran, a study drug that Lily refers to as LY3819469, which is an experimental treatment for elevated lipoprotein (a) (Lp[a]); which is an increase in a type of fat in your blood that is not good for your health. The study will evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
ClinicalTrials.gov Identifier: NCT06292013
See more at https://clinicaltrials.gov/study/NCT06292013
Please reach out to our research team at preventivecvresearch@health.ucsd.edu if you are interested in participating in this clinical trial.
The VINCENT Study
Lp(a)Study Title: A Phase 2 Study to Evaluate the Effect of Obicetrapib alone and in Combination with Evolocumab (Repatha®) on Lipoprotein (a) in Patients with Mild Dyslipidemia: The VINCENT Study
Study Sponsor: NewAmsterdam Pharma B.V.
Brief Summary: In this study, we are exploring the effects of two study drugs—Obicetrapib and Evolocumab—on elevated levels of lipoprotein(a) (Lp[a]), which is linked to a higher risk of cardiovascular diseases such as heart attacks and strokes. While known to reduce LDL (aka your "bad" cholesterol), previous clinical trials have shown these drugs also have an Lp(a) lowering effect . This research takes a novel approach with its focus on the combined impact of a CETP inhibitor (Obicetrapib) and an FDA-approved PCSK9 inhibitor (Evolocumab, also known as Repatha) on Lp(a) levels. We are specifically enrolling participants who have both elevated Lp(a) and mild dyslipidemia.
ClinicalTrials.gov Identifier: NCT06496243
See more at https://clinicaltrials.gov/study/NCT06496243
Please reach out to our research team at preventivecvresearch@health.ucsd.edu if you are interested in participating in this clinical trial.
More clinical trials coming soon